DECLARACIÓN:

ESTE BLOG NO TIENE ANIMO DE LUCRO NI CONFLICTOS DE INTERES. SU ULTIMO FIN ES NETAMENTE EDUCATIVO

viernes, 1 de julio de 2016

Martes de dolor. Martes 5 de Julio 2016

Jose es un paciente de 48 años. Arquitecto. Es deportista y no tiene antecedentes médicos de importancia. 
Hace 3 meses empezó a tener una cefalea temporal izquierda no pulsátil. Por este motivo asistió en 2 oportunidades a urgencias en donde luego de evidenciar un examen neurologico normal, lo manejaron con diclofenaco 75mg con lo que resuelve los síntomas por un periodo limitado de tiempo. 
Consulta a un neurólogo quien solicita una resonancia magnética nuclear que mostró un glioblastoma temporal izquierdo.   
Esta mañana fue llevado a cirugía, una craneotomía temporal izquierda.    Recibió anestesia general total endovenosa con dexmedetomidina (TRIVA). 
Posterior a la inducción fue sometido a una bloqueo de cuero cabelludo con levobupiovacaina al 0,375% y lidocaina al 1% CE. 
Recibió 1 gramo intravenoso de acetaminofén.   
La cirugía sigue un curso normal, sin alteraciones hemodinámicas, con un sangrado controlado. El tiempo quirúrgico fue 6 horas. 
Al finalizar la cirugía se administró 75mg de diclofenaco. 
Recibió ondasetrón 4 mg y omeprazol 40mg. 

Es extubado en salas de cirugía.  
Es trasladado a la UCI quirúrgica en donde llega manifestando dolor severo 9/10.  Su tensión arterial está en 170/100 su frecuencia cardiaca es 108 por minuto. 

Una bienvenida al grupo de Neuoanestesia quienes enriquecerán con su presencia este PBL. 


1. Identifique los problemas del paciente. 
2. Cuales son las fuentes de nocicepción en este tipo de cirugía
3. Cuál es el papel de las técnicas regionales en el manejo analgésico. Cuál es la técnica recomendada para este bloqueo. 
4. Cuál es el nivel de recomendación del uso de AINES en ese tipo de pacientes
5. Cuál es el estado de recomendación del uso de opioides intra y postoperatorios. 

Por favor, referencia sus respuestas . 

No traiga presentaciones en Power Point. No es una charla magistral.

Si piensa que un diagrama, gráfico o fotografía  facilita su explicación por favor envíemelo al correo.  
CARLOSGUERREROMD@ME.COM




sábado, 25 de junio de 2016

Martes 28 de Junio 2016

Adriana es una paciente de 40 años.  Es ama de casa y no tiene antecedentes médicos diferentes al que motiva esta visita a su consultorio. 

Manifiesta que desde que es adolescente generalmente en la época del año cercana a Semana Santa presenta dolor de cabeza severos. Ha tenido años en los que no los presenta. 
En este momento se encuentra sin dolor, pero manifiesta que está en la época en la que la mayoría de las noches presenta crisis de dolor severo hemicraneal derecho, que tiene un énfasis en la región periorbitaria. El examen físico neurológico es normal. 
Estas crisis duran cerca de media hora, son severas 10/10.  Dice que el ojo se hincha y se pone rojo. 
Las crisis de dolor la ponen muy nerviosa e intranquila.   De hecho ha tenido ataques de pánico asociados. 

En el pasado ha tenido muchos analgésicos pero recuerda especialmente amitriptilina, pregabalina, verapamilo, cortisona y sumatriptian.   Nunca le han hecho un bloqueo. 
Está siendo manejada con Litio 600mg al día y para las crisis usa un medicamento llamado Cafergot y se pone una cánula de oxígeno lo cual no está sirviendo. Muchas veces se inyecta diferentes AINES. 
Esta deprimida y asiste a su consulta solicitando ayuda. Ha pensado en quitarse la vida. 

1. Cuál es el problema. 
2. Como se clasifica este tipo de cefalea. Que sistema de clasificación propone
3. Que esquema de tratamiento estructurado, basado en la evidencia propone. 
















domingo, 19 de junio de 2016

Why Should I Take the FIPP Examination?


Philippe Mavrocordatos
MD, FIPP
WIP Honorary Secretary
Lausanne, Switzerland

Dear Friends,

I was recently asked what I would say to someone who was considering taking the FIPP Examination.  When I took my FIPP exam in 2007, I already had 10 years of interventional pain practice, excellent training, and felt quite confident in my daily routine.  By chance, I met some colleagues who suggested me to take the FIPP exam. I did not feel I really needed it, but found the idea interesting.  Well, I didn't know how much this exam would change my professional life.


Locally, my daily practice improved significantly. The FIPP certification made me feel more confident, I was up to date with my readings and also with my techniques.. Interestingly, it also had an important impact on my referrals, as local physicians knew they had a real specialist to talk to and not just another anesthesiologist doing pain.

Nationally
, it helped me build up our interventional pain society, and I based our post-graduate education on clear and validated criteria to set up and develop the pain specialty. I also knew I could count on the support of my FIPP peers for questions and exchanges.

Internationally
, it was probably for me the biggest surprise. I got invited to teach, and to examine colleagues who now are close friends, people with whom I have frequent exchanges. We have common projects and learn from each other.

For me, the FIPP exam and the WIP organization in general changed my understanding of pain and made me a part of a worldwide network; I now feel part of this professional family!

I hope these words will encourage you to study for and take the FIPP Examination in the near future. It changed my life, and will change yours as well!

Cheers,

philippe

For more details about the examination, including sample MCQs and recommended references, please review the FIPP Information Bulletin, available in PDF format at http://bit.ly/fippinfo16.  To apply for the examination, please visit the online application system at http://bit.ly/fippapp.

--------------------------------------
To unsubscribe from this mailing list, please click here

sábado, 18 de junio de 2016

Martes 21 de JUNIO 2016

Como han podido notar, hay una avalancha de información sobre lo que es llamado la epidemia de opioides. ( previamente, varias entradas de este blog han hecho referencia a este tema) .    

La situación es tan compleja en los Estados Unidos,  que su gobierno reconoce que hay más muertes por sobredosis de opioides que por accidentes de tránsito.  Desafortunadamente no tenemos datos de la situación en Colombia. 

Esta situación favorece el desarrollo e impulso de todas las intervenciones analgésicas que son ahorradoras o "reemplazadoras"  de opioides.   Una de estas intervenciones es el desarrollo de nuevos medicamentos como por ejemplo los anestésicos locales de depósito con vidas medias más largas. 




1. Identifique el problema que está detrás de las afirmaciones anteriores. 
2. Que estrategias de ahorro de opioides conoce ? 
3. Explique la farmacología de la bupivacaina liposomal. Que estudios justifican su uso ? En qué situaciones está indicado ? 

MEDSCAPE. America we have a Problem. Solving the opioid overdose epidemic

Alex Cahana, MD | Disclosures

The Current State of the Opioid Abuse Epidemic
Two Princeton economists startled Americans recently when they reported that between 1999 and 2013, white middle-aged men and women in the United States, especially those with a high school education, were dying at an increasing rate from prescription and illegal drug overdose, alcohol and liver-related disease, and suicide.[1] Such results are not news to those engaged in day-to-day patient care; to those patients who continue to endure debilitating pain and chronic disease; or to those who have buried a loved one from a drug or alcohol overdose. Fortunately, there is the impression that finally the government and media are paying attention to this national epidemic.[2] 
Presidential candidates are sharing personal stories of pain and loss and thus diminishing the stigma associated with pain, depression, posttraumatic stress, and addiction. The President's first mention of healthcare in his final State of the Union Address was about the crushing problem of drug abuse. In February 2016, Obama announced his plans to invest over $1.1 billion in the next 2 years to expand access to treatment for prescription drug abuse and heroin use, improve access to the overdose-reversal drug naloxone for first responders, and support targeted enforcement activities.[3] 
The Princeton study also forces us to recognize that drug abuse is not a malady afflicting only poor, minority, inner-city communities but rather is an across-the-country phenomenon, affecting rural white adults in particular.[1] Of note, this mortality trend countering the declining death rates from other chronic diseases demonstrates that the undertreatment of pain among minorities has inadvertently "protected" them from overdose, thus reducing a decades-long death rate gap between white and nonwhite patients. These realizations are driving bipartisan support in Washington that is reflected in the Comprehensive Addiction and Recovery Act (CARA), intended to revise punitive drug policies, promote best medical practices, and strengthen data sharing among states' prescription drug monitoring programs.[4] 

But are these laudable and necessary efforts the right way to go? Will increased access to care for those already harmed by addiction, addressing the enduring shortfalls in prescriber education, and research into alternative abuse-deterrent medications actually reverse this deadly epidemic?
The short answer is maybe but probably not without more initiative. Why so?
A Social Problem, Not Just a Medical Issue
First, researchers are struggling to understand why white individuals, in particular, are doing so poorly with drug abuse. Although there are no definite answers, many speculate that this cohort of patients suffers, in addition to social and economic isolation, from acute job loss. It is known that poverty, stress, and lack of social support are independent risk factors for opioid abuse. Similarly, job loss per se has been found to increase the risk for cardiovascular disease (CVD) and death.[5] Of note, recession alone does not increase CVD mortality; however, when recession is associated with job loss, heart attacks, strokes, and deaths rise. This suggests that increases in stress, despair, and possibly time spent engaging in related unhealthy behaviors often seen with financial insecurity (eg, physical inactivity, smoking, drinking, and drug abuse) may be culprits.
Second, and even more surprising, is that although awareness of the harms of opioid abuse is rising, the overwhelming majority of patients who survived an overdose continue to be prescribed high-dose opioids, often by the same prescriber.[6] It is easy to attribute these results to poor care, bad decisions, or sloppy prescribing, but it might be possible that many of the prescribers simply do not know that their patients are overdosing. Given the fact that there are no widespread systems in place to notify prescribers when overdoses occur, it is highly unlikely that prescribers will suddenly increase the level of medical supervision and care for these patients.
Third, the notion that there is a small group of prolific prescribers who are driving the opioid overdose epidemic is not accurate. The bulk of prescriptions are written by general practitioners trying to help patients with a broad array of health conditions. In fact, the distribution patterns of prescribing opioids among Medicare and Medicaid patients are no different from other drugs given for chronic diseases, where 10% of all drug prescribers account for 60% of all drug prescriptions.[7] These statistics would suggest that focusing on law enforcement, albeit merited, does not warrant significant additional resources to address improper prescribing at large.
Fourth, and most disappointing, is that despite a plethora of local, regional, state, and federal efforts to curb the overdose epidemic, things are actually getting worse. More people died from prescription and illicit drug overdoses over the past year than during any previous year on record.[8] Clearly, there is a need to do a better job in prescribing and intervening before prescription drug misuse or other substance use progresses to addiction. But are these responses a big enough step in the right direction?
Underassessment: The Overlooked Problem
The 18th century French philosopher Voltaire had many amusing quotes about medicine, such as: "common sense is not so common" and "the Art of Medicine consists of amusing the patient, while nature cures the disease." However, there is one quote in particular that is worth mentioning that might provide an overlooked solution for the overdose epidemic. Voltaire said (most probably after a dissatisfying encounter with his physician): "Doctors are men who prescribe medicines of which they know little, to cure diseases of which they know less, in human beings [of whom] they know nothing."[9] This statement is still relevant for current medical practice 250 years later, but is it still accurate?
Clearly the understanding of diseases and pharmacology have infinitely increased since Voltaire's era, a time when the concepts of infections and antibiotics were unimaginable, let alone unknown. Obviously we know much more about how to prescribe medicines and how to cure diseases, but what about knowing our patients? How well do healthcare providers know their patients nowadays; and how does this intimate, context-sensitive, and unbiased knowledge contribute to the decision to prescribe (or not) drugs? When was the last time a healthcare professional used an online multidimensional, patient-reported outcome tool during a routine office visit incorporating data on sleep, movement, and diet based on a wearable FitBit-like device? When was the last time a prescriber was able to show a patient a longitudinal treatment outcome on a dashboard in real time to justify continuing or stopping treatment?
If your answer is never, you probably understand that the problem of medicine in general, and pain medicine in particular, is not the over- or underprescription of opioids, or over- or undertreatment of anything, but rather a fundamental underassessment of complex physical conditions and nuanced life narratives.
So yes, $1 billion funding of appropriate, cost-effective treatments can be expected to help with the current epidemic, but in order to reduce and not just halt rising death rates, prescribers really need to get to know their patients, like Voltaire said. Beyond human contact, professionals need to start quantifying human social traits (ie, phenotypes) at every clinical encounter in addition to their routine use of lab tests and imaging. Insurance companies need to pay for this, so that lack of time will not be an excuse for not measuring behavior, and patients need to have this actionable information (ie, health data) available. Not measuring pain interference, mood, diet, activity, exercise, and sleep limits the understanding of the effects of any therapy and makes prescribers incapable of guiding patients and their families to cope with, and remove, the obstacles that deny them the health and wellbeing they seek.[10] 
References

domingo, 12 de junio de 2016

Martes 14 de Junio. 2016

Hola, este día como antesala a la reunión del departamento de anestesia  del miércoles 15, vamos a discutir las estrategias de manejo analgésico para los pacientes sometidos a hepatectomia.   Por favor, hacer una búsqueda de la literatura actual para por der hacer en la reunión recomendaciones basadas en la evidencia.   Nos vemos 

sábado, 4 de junio de 2016

Junio 7 del 2016

Felipe es un paciente de 52 años quien hace 4 días fue sometido a un reemplazo total de cadera.  Es un paciente con antecedente de obesidad y trastorno de ansiedad. 

Recibió anestesia general sin complicaciones y en el postoperatorio fue manejado por 72 horas con un sistema de analgesia controlado por el paciente de hidromorfona a dosis bajas. Como parte de el protocolo de analgesia multimodal recibió inicialmente acetaminofén 3 gramos por día  y en el último día acetaminofén con hidrocodona (20 mg- día). 

Hoy va a ser dado de alta del hospital, sin embargo el paciente le manifiesta que tiene dolor abdominal y sensación de ¨plenitud¨ abdominal.  Desde hace 5 días no presenta deposición pese a haberlo intentado en múltiples oportunidades.  Su abdomen es blando y depresible. Y manifiesta que en algunos viajes y situaciones de estrés laboral había tenido una situación similar. 

 La rehabilitación quirúrgica es adecuada. 

1. Cuál es el problema. 
2. Que definición aceptada explica este problema 
3. Cuál es la razón fisiopatológica de esta condición (llevar ilustraciones para explicarlos)
4. Que intervenciones profilácticas debieron haberse tenido en cuenta con este paciente. 
5. Cuál es el manejo mas adecuado 
6. Hacer un cuadro comparativo de los diferentes fármacos aprobados para esta condición que explique su farmacología. (Enviar a mi correo para subirlos al blog)
7. Cómo va a manejarlo (basado en el punto 6)



Saludos 

Nicolás Dussan hizo esta tabla : 


Andrés Obando mandó esta gráfica 



 

lunes, 30 de mayo de 2016

31 de Mayo 2016

Mañana no habrá reunión ya que el auditorio va hacer utilizado para los exámenes de los residentes de anestesia. Nos vemos en ocho días

lunes, 16 de mayo de 2016

Martes 16 de Mayo

Hola. Mañana vamos a revisar la nueva base de datos de la clínica del dolor y su funcionamiento. 
Los internos y estudiantes no deben asistir. 

Gracias 

sábado, 7 de mayo de 2016

Martes 10 de Mayo

Este día vamos a revisar los 2 proyectos de investigación que tiene los Fellows Ximena Beltran y Nicolás Dussan. 

Los residentes deben asistir. 
Los internos y estudiantes estan libres ! 


Nos vemos